News

Article

Pharmaceutical Technology

Pharmaceutical Technology-09-02-2003
Volume27
Issue 9

The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride

Author(s):

Kilambi Pundarikakshudu, PhD

The study presented in this article used a controlled-porosity osmotic pump, which was prepared in the form of a bilayered tablet containing a drug compartment and an osmogen layer for the delayed release of diltiazem HCI.

External Link - article-70094.pdf

Articles in this issue
September 2003
In the Spotlight September 2003
Counterfeiting, Compliance, and Controls
September 2003
The Fabrication And Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System with Diltiazem Hydrochloride
Disposable Filtration Lightens Cleaning and Validation Load
CROs Hoping for Research Burst in Second Half of 2003
Positron Emission Particle Tracking Studies of a Wurster Process for Coating Applications
Improved Blister Packaging Benefits Consumers, Caregivers, and Drug Makers

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 22nd 2025

AstraZeneca to Invest $50 Billion in US Manufacturing and R&D

Susan Haigney
The company will build a multi-billion-dollar drug manufacturing center in Virginia that will focus on chronic diseases, as well as facilities in California, Indiana, Maryland, Massachusetts, and Texas.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com
July 21st 2025

FDA Appoints New CDER Director, George Tidmarsh

Susan Haigney
George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine program, has been appointed as the new director of the Center for Drug Evaluation and Research.
3d render, number six glowing in the dark, pink blue neon light | Image Credit: © NeoLeo - stock.adobe.com
July 17th 2025

The 6-Stage Compounding Framework Every Pharmaceutical Manufacturing Professional Should Know

Christopher Cole
A structured, risk-based framework for pharmaceutical compounding that enhances quality, regulatory compliance, and process consistency.